SecBot SecBot
8-K ·Filed May 7, 2026

PRVA

Privia Health Group, Inc.
MIXED
Impact 6/10
Horizondays Processed6mo ago SEC0001759655-26-000027
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The massive GAAP EPS miss vs consensus will pressure the stock near-term, but the strong revenue beat, 36% Adjusted EBITDA growth, and reaffirmed guidance suggest underlying business momentum. Watch for the conference call to understand the GAAP EPS miss drivers (likely stock-based comp and higher tax provision) and whether the Street focuses on adjusted metrics or GAAP disappointment.

DirectionMixed
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$23.99
T+0 close · May 7, 2026 · via day close
Latest settled
−0.83%
T+60 · $23.79
Vs SPY
−4.67%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $23.99entry
  2. T+1 · 6mo ago −3.88%α −4.71% · $23.06
  3. T+5 · 6mo ago −5.67%α −7.17% · $22.63
  4. T+20 · 6mo ago −13.88%α −17.02% · $20.66
  5. T+60 · 4mo ago −0.83%α −4.67% · $23.79

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Privia Health reported Q1 2026 revenue of $603.8M (+25.8% YoY) and GAAP EPS of $0.02, well below the $0.25 consensus estimate. Adjusted EBITDA grew 36.3% to $36.7M, and the company reiterated full-year 2026 guidance across all key metrics while raising its Attributed Lives outlook. The GAAP EPS miss is significant, but the strong revenue beat, robust operational metrics, and reaffirmed guidance provide a mixed picture.

Key Financial Metrics

EPS
$0.02
est $0.25 · -92.0%
Revenue
$603.8M
est $561.9M · +7.5% · +25.8% YoY
Rating
strong miss
Guidance
$2,350M-$2,450M
maintained
Free Cash Flow
-$49.5M
Gross Margin
20.8%

Key Facts

  • Q1 2026 revenue of $603.8M (+25.8% YoY) beat consensus of $561.9M
  • GAAP EPS of $0.02 missed consensus of $0.25 by 92%
  • Adjusted EBITDA of $36.7M, +36.3% YoY
  • Full-year 2026 guidance reiterated across all key metrics; Attributed Lives guidance raised to 1.60M-1.625M
  • Practice Collections of $914.8M, +14.6% YoY
  • Operating cash flow used $49.5M in Q1 vs $24.1M used in Q1 2025
  • Cash balance of $419.5M, down from $479.7M at year-end 2025

Financial Impact

Revenue beat by $41.9M (+7.5% vs consensus); GAAP EPS missed by $0.23 (-92% vs consensus); Adjusted EBITDA grew 36.3% YoY

revenueepsadjustedEbitdacashFlow

Risk Factors

  • GAAP EPS miss of 92% vs consensus could trigger significant sell-off
  • Operating cash flow negative $49.5M vs negative $24.1M a year ago, driven by large accounts receivable build
  • Cash balance declined $60.2M in the quarter
  • High stock-based compensation ($21.9M) continues to depress GAAP profitability

Market Snapshot

Exchange
Nasdaq
Sector
Services-Health Services
Analyst Consensus
89% bullish (27 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001759655-26-000027
Document: prva-20260507.htm0001759655-26-000027
Document: 0001759655-26-000027-index-headers.html0001759655-26-000027
Document: 0001759655-26-000027-index.html0001759655-26-000027
Document: 0001759655-26-000027.txt0001759655-26-000027
8-K Data (Synthetic)0001759655-26-000027

Track record

20 reports on PRVA

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +10.73% at T+60 after the Mar 9, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Mixed 6/10 No price data
  2. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $23.94 to $23.67 Now $25.26 −5.51% ▲ +1.13% +4.42% vs SPY
  3. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $21.28 to $24.54 Now $25.26 +18.70% ▲ +15.32% +15.24% vs SPY
  4. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $21.48 to $24.42 Now $25.26 +17.60% ▲ +13.69% +16.39% vs SPY
  5. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $20.30 to $21.67 Now $25.26 +24.43% ▲ +6.75% +7.73% vs SPY
  6. Jul 13, 202618w ago Insider Cluster Neutral 3/10 Entry $28.03 to $26.26 Now $25.26 −9.88% ▼ −6.31% −5.02% vs SPY
  7. Jul 9, 202618w ago Insider Cluster Neutral 3/10 Entry $27.49 to $26.90 Now $25.26 −8.11% ▼ −2.15% −0.60% vs SPY
  8. Jul 7, 202618w ago Insider Cluster Neutral 3/10 Entry $27.21 to $28.10 Now $25.26 −7.17% ▲ +3.27% +2.01% vs SPY
  9. Jul 7, 202618w ago Press Release Neutral 1/10 Entry $27.23 to $28.03 Now $25.26 −7.23% ▲ +2.94% +2.39% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Neutral 3/10 Entry $27.36 to $27.77 Now $25.26 −7.68% ▲ +1.50% +0.57% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 8h 9m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026